FAST & NON INVASIVE SOLUTION TO AROUND THE CLOCK BLOOD SUGAR MONITORING
Alivecel delivers painless, non invasive and economically feasible innovations to help enhance the quality of life for our customers and improve the over all ease of glucose monitoring using a remote technology, improving the overall quality of patient life.
A single injectable biosensor, no bigger that a grain of rice, is injected under the skin in a simple one time procedure. The sensor is self rechargeable and capable of around the clock blood sugar monitoring. The sensor sends real time data to a smart phone application that can be shared with health care providers and other family members, and provide alarms in the case of blood sugar irregularities.
Its simple, painless, economically viable, and provides doctors and researchers with historic and real time data. Patients will no longer have to suffer burdensome time consuming and painful monitoring.
To provide the best glucose monitoring for people with diabetes all over the world.
We are committed to developing innovative ideas in the realm of biosensors that will provide diabetics a non invasive solution to around the clock blood sugar monitoring.
HOW WE DO IT?
Through innovation and proven practices, Alivecel solves some of the most pressing problems facing the patients we aim to serve. Alivecel utilizes a combination of technologies developed by both US Universities and leading researcher facilities from around the world. Our researches have an international reach, a global view, but a highly focused common goal. We combine the leading technologies of this field in innovative and practical ways.
Gerard H. Bencen, Esq., is a seasoned attorney and business professional with experience in protecting and translating basic scientific discoveries into commercial products. Deep and broad experience in the pharmaceutical, allograft, and medical device fields, with particular strength in protecting, evaluating, licensing and enforcing intellectual property rights in the United States.
Gerard holds various degrees in biochemistry, biophysics and molecular biology, and past positions with Merck.
He also served as General Counsel to NASDAQ listed allograft production company RTI Surgical (RTIX), and founded Bencen & Van Dyke, PA and Patent-Arts law practices. Over the years he has supported numerous start-up companies, collaborated with University Technology Transfer offices, and investment diligence teams, to manage legal exposure, advise senior management, and successfully concluded major investment and licensing deals.
Mark Glazer is a molecular biologist, inventor, and Chief Technology Officer (CTO) at ALIVECEL LLC. He has deep experience across various fields, including genetic engineering. His main speciali-sation is in molecular and synthetic biology, combined with micro-electronics and nanotechnology. Mark also holds various scientific interests in the arising field of astrobiology. As a scientist, he’s combining different branches of science to create novelty solutions for modern problems. Mark Glazer graduated with a degree in Molecular Biology from the University of Warsaw and The Polish Academy of Sciences. Previously, as the head scientist at a private laboratory in Glasgow, Scotland - BIOCITY, he investigated new approaches for decontamination and pathogen detection in medical equipment. Previous to that, at Warsaw University, he researched regulatory segments of mRNA - called Riboswitches, that can bind to small molecules, resulting in a change in production of proteins of pathogenic bacteria. Additionally, he did research at Poland’s National Institute of Oncology - Marie Skłodowskiej-Curie. He was also the first Polish biologist to investigate “assessment of the ability of microorganisms to survive in low Earth orbit.” In his free time, Mark writes pop-science articles for Focus Magazine.
ALIVECEL LLC has concluded an MOU enabling immediate cooperation with a Warsaw Stock Exchange listed health and biotech company Hemp&Wood S.A. Both companies foresee this cooperation transforming into a Joint Venture, with the combined focus on developing new technology that will allow the use of the ALIVECEL BIOCAPSULE SYSTEM for real time in vivo detection of various markers including virus related.
The goal is to offer a low cost monitoring and detection system, that could transmit early warning signals to users and their health care providers.
© 2019 ALIVECEL - All Rights Reserved